Takeda Pharmaceutical entered into a 364-day bridge credit agreement for an aggregate principal amount of up to $30.85 billion to finance its acquisition of Shire. JPMorgan served as administrative agent on the transaction.
Shire and Baxalta have reached an agreement under which Shire will combine with Baxalta. Shire secured a $18 billion bridge facility commitment from a lender group led by Barclays Bank as agent
Shire and ViroPharma announced the companies have entered into a merger agreement in which Shire will acquire all the outstanding shares of ViroPharma. Lazard and Morgan Stanley are acting as joint financial advisors to Shire.